UGT2A2 is a UDP-glucuronosyltransferase that catalyzes phase II biotransformation through glucuronidation, conjugating lipophilic substrates with glucuronic acid to enhance water solubility and facilitate excretion 1234. The enzyme is essential for eliminating and detoxifying drugs, xenobiotics, and endogenous compounds 24. UGT2A2 demonstrates high activity in bile acid glucuronidation, particularly for cholic acid-24G and chenodeoxycholic acid-24G formation with low micromolar affinity 4. It catalyzes estradiol glucuronidation 13 and contributes to detoxification of polycyclic aromatic hydrocarbons and other tobacco carcinogens 5. Notably, UGT2A2 is predominantly expressed in nasal mucosa 6, linking it to olfactory dysfunction. Genetic variants near UGT2A2 associate with anosmia in COVID-19 patients 78, while UGT2A2 expression is significantly downregulated in meningiomas of current smokers, suggesting altered xenobiotic metabolism in smoking-related cancers 9. The enzyme participates in glucuronidation of hydroxypropranolol metabolites alongside other UGTs 10, highlighting its broader role in drug metabolism.